C Austin Zamarripa, Hayleigh E Tilton, Spencer Lin, Edward J Cone, Ruth E Winecker, Ronald R Flegel, David Kuntz, Melissa Beals, Martin Jaques, Michael Clark, Eric R Welsh, Lynn Wagner, Marcel O Bonn-Miller, Ryan Vandrey, Tory R Spindle
Products containing cannabidiol (CBD) have proliferated after the 2018 Farm Bill legalized hemp (cannabis with ≤0.3% delta-9-tetrahydrocannabinol, Δ9-THC). CBD-containing topical products have surged in popularity but controlled clinical studies on them are limited. This study characterized the effects of five commercially available hemp-derived high CBD/low Δ9-THC topical products. Healthy adults (N=46) received one of six study drugs: a CBD-containing cream (N =8), lotion (N =8), patch (N =7), balm (N=8), gel (N =6), or placebo (N=9; matched to an active formulation)...
January 11, 2024: Journal of Analytical Toxicology